Payment overview · 2025
General Payments
$58.91
2 reported records · 2 companies
Healthcare provider profile · identity verified
Ryan Nerland, M.D.
Allopathic & Osteopathic Physicians|Pediatrics · MEDINA, TN · NPI 1972700748
Verified facts
What the public records show
CMS Open Payments records show Ryan Nerland, M.D. received $58.91 in general payments during 2025 across 2 reported records.
Lilly USA, LLC accounted for 76.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.00 | 76.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $13.91 | 23.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Education | $45.00 | 1 |
| Food and Beverage | $13.91 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
65 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 400 | 103 |
| Pantoprazole Sodium | Pantoprazole Sodium | 354 | 88 |
| Lisinopril | Lisinopril | 329 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 326 | 87 |
| Alprazolam | Alprazolam | 311 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 305 | 77 |
| Furosemide | Furosemide | 261 | 75 |
| Omeprazole | Omeprazole | 256 | 73 |
| Gabapentin | Gabapentin | 250 | 60 |
| Meloxicam | Meloxicam | 212 | 60 |
| Losartan Potassium | Losartan Potassium | 201 | 58 |
| Metformin Hcl | Metformin Hcl | 195 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 189 | 39 |
| Lorazepam | Lorazepam | 188 | 31 |
| Pregabalin | Pregabalin | 171 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 150 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 142 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 136 | 35 |
| Sertraline Hcl | Sertraline Hcl | 129 | 31 |
| Trazodone Hcl | Trazodone Hcl | 127 | 41 |
| Clonazepam | Clonazepam | 124 | 20 |
| Eliquis | Apixaban | 117 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 117 | 29 |
| Simvastatin | Simvastatin | 114 | 29 |
| Memantine Hcl | Memantine Hcl | 113 | 16 |
| Carvedilol | Carvedilol | 109 | 33 |
| Prednisone | Prednisone | 106 | 67 |
| Potassium Chloride | Potassium Chloride | 105 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 97 | 15 |
| Famotidine | Famotidine | 93 | 25 |
| Glimepiride | Glimepiride | 93 | 25 |
| Montelukast Sodium | Montelukast Sodium | 88 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 82 | 25 |
| Celecoxib | Celecoxib | 81 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 12 |
| Baclofen | Baclofen | 77 | 29 |
| Nortriptyline Hcl | Nortriptyline Hcl | 74 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 18 |
| Ondansetron Odt | Ondansetron | 68 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 18 |
| Tramadol Hcl | Tramadol Hcl | 66 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 65 | 35 |
| Jardiance | Empagliflozin | 65 | 16 |
| Levofloxacin | Levofloxacin | 64 | 51 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 15 |
| Ozempic | Semaglutide | 60 | 16 |
| Allopurinol | Allopurinol | 59 | 15 |
| Buspirone Hcl | Buspirone Hcl | 59 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 16 |
| Metformin Hcl Er | Metformin Hcl | 57 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 51 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 50 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 15 |
| Fenofibrate | Fenofibrate | 49 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 12 |
| Spironolactone | Spironolactone | 47 | 14 |
| Januvia | Sitagliptin Phosphate | 46 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 14 |
| Mirtazapine | Mirtazapine | 46 | 11 |
| Clonidine Hcl | Clonidine Hcl | 45 | 14 |
| Donepezil Hcl | Donepezil Hcl | 45 | 13 |
| Meclizine Hcl | Meclizine Hcl | 44 | 14 |
| Midodrine Hcl | Midodrine Hcl | 44 | 14 |
| Promethazine Hcl | Promethazine Hcl | 43 | 15 |
| Aripiprazole | Aripiprazole | 42 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | suppressed |
| Sucralfate | Sucralfate | 42 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 40 | suppressed |
| Dutasteride | Dutasteride | 40 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 13 |
| Lovastatin | Lovastatin | 39 | suppressed |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Glipizide | Glipizide | 38 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | 11 |
| Warfarin Sodium | Warfarin Sodium | 37 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | 11 |
| Levetiracetam | Levetiracetam | 36 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | 11 |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Diazepam | Diazepam | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 33 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Haloperidol | Haloperidol | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 20 |
| Nystatin | Nystatin | 27 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 17 |
| Clindamycin Hcl | Clindamycin Hcl | 25 | 24 |
| Fluconazole | Fluconazole | 25 | 19 |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 24 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 11 |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Vraylar | Cariprazine Hcl | 21 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 13 |
| Rexulti | Brexpiprazole | 20 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 18 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Dexmethylphenidate Hcl | Dexmethylphenidate Hcl | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Cimetidine | Cimetidine | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 13 |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 13 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $58.91 · 2 records | Lilly USA, LLC | CAPLYTA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error